Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BIBF + Paclitaxel|DRUG: Paclitaxel
Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborators: Hospital Universitario de Fuenlabrada|M.D. Anderson Cancer Center|Hospital Universitari de Bellvitge|Grupo Espanol de Investigacion del Cancer de Mama